GlassScriptPhysician profile
Mohinder Partap
NPI 1235137035
$11,922.31
in general payments reported to CMS, 2019-2025
43 companies · $2,599 in 2025
The $2,599 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,737 · 2020: $550 · 2021: $1,644 · 2022: $2,226 · 2023: $1,374 · 2024: $1,792 · 2025: $2,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,761 · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,760.59 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,418.20 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,380.01 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,369.23 | 2019-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $1,046.18 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $818.48 | 2019-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $771.47 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $672.04 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $536.92 | 2019-2025 | Rexulti, Vyepti |
| Janssen Pharmaceuticals, INC | $523.59 | 2019-2025 | Invega Sustenna, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $503.98 | 2019-2025 | Trintellix, Advate |
| Allergan, INC. | $408.06 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $358.84 | 2019-2024 | Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $267.10 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $234.18 | 2021-2025 | Qelbree |
| Neos Therapeutics, LP | $176.66 | 2019-2025 | Adzenys Xr-Odt |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $175.63 | 2021 | |
| Axsome Therapeutics, INC. | $148.94 | 2022-2025 | Auvelity |
| Noven Therapeutics, LLC | $113.99 | 2022-2024 | Xelstrym, Secuado |
| Noven Pharmaceuticals, INC. | $100.91 | 2024 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $81.48 | 2019-2024 | |
| Adlon Therapeutics L.P. | $76.48 | 2021 | |
| Ucb, INC. | $73.64 | 2024-2025 | Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $69.04 | 2019-2021 | |
| Tris Pharma INC | $63.20 | 2022-2025 | Dyanavel Xr |
| Neurelis, INC. | $57.94 | 2023-2025 | Valtoco |
| Corium, LLC | $45.39 | 2021-2023 | Azstarys |
| Avanir Pharmaceuticals, INC. | $45.23 | 2019 | |
| Harmony Biosciences LLC | $41.14 | 2025 | |
| Indivior INC. | $40.96 | 2019 | |
| Bioxcel Therapeutics, INC. | $40.63 | 2023 | Igalmi |
| Idorsia Pharmaceuticals US INC | $36.59 | 2022-2023 | Quviviq |
| Sk Life Science, INC. | $30.29 | 2025 | |
| Merck Sharp & Dohme LLC | $28.08 | 2021-2023 | Belsomra |
| Almatica Pharma LLC | $26.80 | 2021-2023 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $19.37 | 2025 | Jornay Pm |
| Octapharma USA, INC. | $17.67 | 2025 | Panzyga |
| Itamar Medical INC | $16.88 | 2025 | Watchpatone |
| Vertical Pharmaceuticals, LLC | $15.65 | 2019 | |
| Tanabe Pharma America, INC. | $15.51 | 2023 | |
| Acadia Pharmaceuticals INC | $14.95 | 2023 | Nuplazid |
| Kyowa Kirin, INC. | $14.51 | 2024 | Nourianz |
| Shire North American Group INC | $13.64 | 2019 | |
| Eisai INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohinder Partap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.